NOIDS.wiki
Kalkulačka
Obchod Kalkulačka potence
Věda o konopí

THCV (Tetrahydrocannabivarin): Specs, Evidence, Decarb & Infusion

Cannabinoid index · Dose-dependent

Dose-dependent effectNot approvedWADA-prohibitedFat-soluble

THCV (tetrahydrocannabivarin) is a minor cannabinoid and the propyl analog of THC. Its effect is dose-dependent: at low doses it behaves more like a CB1 blocker and is not intoxicating, while at higher doses it can be mildly intoxicating, generally weaker and shorter than THC. It has drawn interest for appetite and metabolic research, with only small early human studies.

Specification
Compound
THCV (Tetrahydrocannabivarin)
Acid precursor
THCVA
Classification
Phytocannabinoid (propyl analog of THC)
CAS number
31262-37-0
Molecular formula
C19H26O2
Molecular weight
286.41 g/mol
Intoxicating
Dose-dependent: not at low doses, mildly at high doses
Solubility
Fat-soluble; poorly water-soluble

Decarboxylation & infusion

Acid form
THCVA, the form in raw flower
Dekarboxylace
THCVA converts to THCV with heat over time
Approx. activation
Broadly similar to THC, roughly 105 to 130°C
Infusion
Fat-soluble, so it transfers into oils and butter
Availability
Present at meaningful levels only in specific cultivars; a trace in most flower

See the tabulkou teplot dekarboxylace.

Evidence & status
Approval status
Not approved. Not a component of any approved drug.
European status
Not authorised. No monograph.
Strongest support
Small early human studies plus animal and cell work
Competitive sport
Prohibited in-competition by WADA (cannabinoids, CBD excepted).
Lab workAnimal studiesHuman studiesApproved label

Reviewed 2026-09-04. Not legal or medical advice.

What the published literature examined

THCV’s dose-dependent pharmacology at the CB1 receptor (antagonist at low doses, partial agonist at higher doses) is described in animal and cell studies. There is limited early human work: a small randomised study examined THCV and glycaemic control in people with type 2 diabetes (Jadoon et al., Diabetes Care, 2016). Appetite and metabolic effects are the main research angle, but the human evidence base is small.

What is established, and what is not

Established: that THCV is a real cannabinoid with dose-dependent CB1 activity, and that a small human study has been conducted. Not established: any approved use or robust clinical benefit; the human evidence is early and small. Marketing that frames THCV as a proven appetite suppressant or “diet weed” overstates it. This page describes the compound and summarises research; it is not medical advice.

Sources

  • Jadoon KA, et al. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Type 2 Diabetes. Diabetes Care. 2016;39:1777-1786. PubMed
  • Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: THC, CBD and THCV. Br J Pharmacol. 2008;153:199-215. PubMed
  • Registered human studies for tetrahydrocannabivarin. ClinicalTrials.gov
  • World Anti-Doping Agency. Prohibited List (cannabinoids, CBD excepted). wada-ama.org

Často kladené otázky

Does THCV get you high?

It depends on the dose. At low doses THCV behaves more like a CB1 blocker and is not intoxicating; at higher doses it can be mildly intoxicating, generally weaker and shorter than THC.

Is THCV “diet weed”?

That nickname comes from appetite and metabolic research, but the human evidence is small and early. It is not a proven appetite suppressant.

Why is THCV rare?

Most cannabis contains only a trace. Meaningful levels appear in specific cultivars, which is why THCV-rich products are uncommon.

Part of the cannabinoid index.

Educational information about a compound. Not medical advice or guidance on use.

Tento článek je pouze pro vzdělávací účely. Vždy dodržujte místní zákony týkající se přípravy a používání konopí.

Scroll to Top